Canada - français - Health Canada

mylan pharmaceuticals ulc - prégabaline - capsule - 50mg - prégabaline 50mg - miscellaneous anticonvulsants

Canada - français - Health Canada

mylan pharmaceuticals ulc - prégabaline - capsule - 75mg - prégabaline 75mg - miscellaneous anticonvulsants

Canada - français - Health Canada

mylan pharmaceuticals ulc - prégabaline - capsule - 150mg - prégabaline 150mg - miscellaneous anticonvulsants

Canada - français - Health Canada

mylan pharmaceuticals ulc - prégabaline - capsule - 300mg - prégabaline 300mg - miscellaneous anticonvulsants

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymphome À cellules b - agents antinéoplasiques - polivy en combinaison avec bendamustine et rituximab est indiqué pour le traitement des patients adultes en rechute/réfractaire diffus à grandes cellules b lymphome (lmnh) qui ne sont pas des candidats pour la greffe de cellules souches hématopoïétiques. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - néoplasmes du sein - agents antinéoplasiques - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppresseurs - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - des sérums et immunoglobulines, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. voir les sections 4. 4 et 5.

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymphome folliculaire - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophtalmologiques - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).